Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic options. Within this broad context, discussions of osteoporosis management and the use of bisphosphonates like Fosamax have been framed primarily as clinical considerations for patients and healthcare providers. The established narrative focuses on treatment efficacy, bone density outcomes, and routine side effect profiles typical of pharmaceutical interventions. Transitioning from this general health perspective toward a more specialized occupational exposure concern requires a shift in analytical focus. While the general public encounters Fosamax through prescription use, the manufacturing and distribution chain introduces a distinct set of exposure pathways. Workers involved in the production, packaging, or quality control of bisphosphonate compounds may face repeated contact with raw materials or airborne particulates during industrial processes. This occupational context raises questions about cumulative exposure levels that differ fundamentally from therapeutic dosing regimens.

Bridging to Occupational Hazard Evaluation

The bridge concept here pivots from patient-centered health information to industrial hygiene considerations. Specifically, the known association between Fosamax and osteonecrosis of the jaw—a condition typically discussed in clinical settings—becomes relevant when examining workplace environments where chronic low-level exposure could occur. This transition reframes the scientific evidence from a treatment risk assessment to an occupational hazard evaluation, without delving into mechanistic claims or citing specific studies. The focus remains on the shift in exposure context rather than the disease process itself.

Fosamax and Osteonecrosis of the Jaw: Clinical Evidence

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation often involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes of jaw necrosis, such as malignancy or radiation therapy.

Scientific Evidence Linking Fosamax to ONJ

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. First, clinical reports have documented ONJ in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that while ONJ is a known risk, its incidence in clinical trials may be low (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate, indicating a causal relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental procedures or infection. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has provided insights into jawbone-specific responses. Studies using estrogen-deficient rats have examined the effects of bisphosphonate treatment on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These investigations help understand how bisphosphonate-related osteonecrosis of the jaw develops, particularly in the context of postmenopausal osteoporosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Causation Considerations

Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the condition, its association with dental procedures, and known risk factors. However, the warning does not provide a precise incidence rate or a definitive timeline for risk, which may leave some patients and clinicians uncertain about the magnitude of the risk. The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term use may increase the risk of ONJ, but the label does not explicitly quantify this risk. For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In some cases, symptoms may appear after years of use. The presence of other risk factors, such as dental procedures or cancer therapy, can complicate the attribution of causation. However, the recurrence of symptoms upon rechallenge with bisphosphonates provides strong evidence of a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while taking Fosamax should discontinue the drug if severe symptoms develop, as most patients have relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure and documented harm is variable. ONJ can occur within days to months of initiating Fosamax, but it is more commonly associated with long-term use, particularly in patients with additional risk factors. The risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who have been on Fosamax for several years, the cumulative risk of ONJ may be higher, especially if they undergo dental procedures. The label advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, the scientific evidence establishes a causal link between Fosamax and osteonecrosis of the jaw, supported by clinical reports, mechanistic studies, and animal models. The risk is influenced by patient-specific factors and duration of exposure. While warnings exist in the prescribing information, they may not fully convey the variability in onset or the magnitude of risk for individual patients. Clinicians should weigh the benefits of Fosamax for osteoporosis treatment against the potential for ONJ, particularly in patients with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The scientific evidence includes clinical reports documenting ONJ in patients taking Fosamax, recurrence of symptoms upon rechallenge with bisphosphonates indicating a causal relationship, and mechanistic studies showing that Fosamax inhibits osteoclast activity, impairing jawbone repair. Animal models have also provided insights into jawbone-specific responses to alendronate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

The time to onset of symptoms can vary from one day to several months after starting the drug, but it is more commonly associated with long-term use. The risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.